Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Oct 22;8(20):5342-5343.
doi: 10.1182/bloodadvances.2024014118.

CARs to the rescue: rare aggressive lymphoma gets a power up

Manali Kamdar  1
Affiliations
Comment

CARs to the rescue: rare aggressive lymphoma gets a power up

Manali Kamdar. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.K. reports research support/funding from Novartis; consultancy fees from AbbVie, AstraZeneca, Celgene/Bristol Myers Squibb, BeiGene, and Genentech; is a member of the speaker's bureau for Seagen; and serves on data monitoring committees for Celgene and Genentech.

Comment on

  • CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
    Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter LG, Sauter C, Hamadani M, Herrera A, Shouval R, Shadman M. Pophali PA, et al. Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863. Blood Adv. 2024. PMID: 38985302 Free PMC article.

References

    1. Pophali PA, Fein JA, Ahn KW, et al. CD19-directed CART therapy for T cell/histiocyte rich large B-cell lymphoma. Blood Adv. 2024;8(20):5290–5296. - PMC - PubMed
    1. Chan WC. Immune escape mechanisms for TCRLBCL. Blood. 2021;137(10):1274–1276. - PMC - PubMed
    1. Nair R, Ogundipe I, Gunther J, et al. Outcomes in patients with relapsed refractory T-cell/histiocyte-rich large B-cell lymphoma treated with CAR-T cell therapies or salvage chemotherapy - a single-institution experience. Blood. 2023;142(suppl 1):6327–6329.
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. - PMC - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. - PubMed

MeSH terms

Substances